2024 Sept 24 - Expand Multiomic Evaluation of Cell Therapy Spatial Distribution and Functional Activity using RNAscope ISH Services
Eric Starr, PhD
Scientific Service Advisor ACD, a Bio-Techne Brand
Watch Video:
Outline:
RNAscope in situ hybridization technology enables specific spatial multiomic detection of RNA and protein biomarkers in engineered therapeutic cells and tissues. Our unique probe design capabilities allow for differentiation of the therapeutic cells from endogenous un-transduced cells within the tumor microenvironment (TME). RNAscope probes can be multiplexed easily with other probes to assess activation state, e.g., IFNG and GZMB, as well as with immunohistochemistry (IHC) and immunofluorescent (IF) detection of CD3, CD4, CD8-positive T cells. These assays are used to monitor efficiencies of cell therapies in post-treatment patient biopsies and in preclinical animal models for safety and efficacy.
In this webinar, we will discuss how the Professional Assay Services (PAS) team will partner with you to help visualize and quantify CAR/TCR T cell infiltration and activation in-tumor and off-tumor tissues as well as to simultaneously detect CAR/TCR vector and cytokines, T cell markers, or other cell-type markers.
Learning Objectives:
- Characterize CAR T spatial distribution and safety profile across pre-clinical and clinical samples Combine the RNAscope multiplex fluorescent ISH assays with IHC or IF to simultaneously detect RNA and proteins
- Multiplex RNAscope ISH fluorescent assays with IHC or IF to simultaneously detect RNA and proteins
- Detect simultaneously CAR/TCR T cells with cytokines, immune cell markers and target antigens
- Measure and quantify distribution of CAR T and TCR T cell therapies in the tumor and stromal compartment
- Perform patient biopsy analysis to link cell therapy pharmacokinetics / pharmacodynamics and efficacy
